Mandate

Vinge advises Axcel in connection with the acquisition of Progrits, a leading software company in vertical software and information services

Progrits consists of ten businesses that develop specialised solutions within transport and logistics, vehicle digital solutions and integrated e-commerce. The B2B software company simplifies and automates customer information handling and workflows for approximately 5,000 Nordic and international customers.

The acquisition is subject to approval from applicable competition authority.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Nando Basic and Josef Groow (M&A), Mathilda Persson and Alva Skott (Commercial Agreements), August Ahlin (Banking and Financing), Madelene Andersson (Real Estate), Julia Löfqvist (Compliance), Tove Hallbäck (Employment), Lisa Hörnqvist (IT and GDPR), Arvid Axelryd and Felizia Wiker (Intellectual Property), Sebastian Örndahl, Victoria Fredén and Hampus Peterson (Merger filing) and Ellinore Boström Andersson (Project Assistant).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026